In Pulmonary arterial hypertension (PAH) Pulmonary arterial hypertension can cause shortness of breath, tiredness, dizziness, chest pain and swelling in your ankles and legs. It is caused by thickening of walls of the arteries that supply your lungs making it hard for blood to get through. Bosentan 125 Tablet relaxes the blood vessels and can help lower the blood pressure in the arteries of your lungs. You will be able to carry out your daily activities more easily and feel less tired or dizzy.
Bosentan 125 Tablet may cause excessive drowsiness with alcohol.
Bosentan 125 Tablet is highly unsafe to use during pregnancy. Seek your doctor's advice as studies on pregnant women and animals have shown significant harmful effects to the developing baby.
Bosentan 125 Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Bosentan 125 Tablet may cause side effects which could affect your ability to drive. As Bosentan 125 Tablet can induce hypotension (decrease of your blood pressure) which can make you feel dizzy and this can affect your ability to drive.
Bosentan 125 Tablet is safe to use in patients with kidney disease. No dose adjustment of Bosentan 125 Tablet is recommended.
Bosentan 125 Tablet should be used with caution in patients with liver disease. Dose adjustment of Bosentan 125 Tablet may be needed. Please consult your doctor. Use of Bosentan 125 Tablet is not recommended in patients with moderate and severe liver disease.
If you miss a dose of Bosentan 125 Tablet, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular schedule. Do not double the dose.
FDC Ltd | B-8, MIDC Area, Waluj - 431 136, Dist. Aurangabad, Maharashtra
Marketer/Manufacturer: Abbott || ₹14.5/tablet (25% cheaper)
No customer reviews yet.
FDA approved prescribing information. Levocitrizine; 1995 [revised May 2007]. [Accessed 01 Apr. 2019] (online) Available from: Read More
European Medicne Agency. Revised assessment report: Ambroxol and bromhexine containing medicinal products. 2015. [Accessed 01 Apr. 2019] (online) Available from: Read More
ScienceDirect. Ambroxol. [Accessed 01 Apr. 2019] (online) Available from: Read More
Levocitrizine. Slough, Berkshire: UCB Pharma Limited; 2007 [revised 27 Mar. 2019]. [Accessed 01 Apr. 2019] (online) Available from: Read More
Marketer/Manufacturer: Cipla Ltd || ₹14.5/tablet (25% cheaper)
Marketer/Manufacturer: Lupin Ltd || ₹14.5/tablet (25% cheaper)
Marketer/Manufacturer: Natco Pharma Ltd || ₹14.5/tablet (25% cheaper)
Marketer/Manufacturer: Lupin Ltd || ₹14.5/tablet (25% cheaper)
Marketer/Manufacturer: Sun Pharmaceutical Industries Ltd || ₹14.5/tablet (25% cheaper)